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Is Pfizer-Wyeth merger aligned with value creation in the pharmaceutical industry? 
This empirical research evaluates whether the Pfizer-Wyeth merger created value for 
shareholders, trying to assess if the specific case study is in line with the principal pattern of 
the industry. In order to achieve these goals, a detailed value creation appraisal is 
implemented through market reaction measurement at the announcement dates of acquisition. 
Afterward, a statistical regression has been performed determining which factors mainly 
affect enterprise’s performance. The conclusion suggests that the deal’s value creation is 
aligned with the pharmaceutical industry trend and that company performance is affected by 
financing structure, EPS and transaction size.  
 


















Ever more attention is being paid at mergers and acquisitions by enterprises working in 
several sectors and, above all, by pharmaceutical firms. The rationale behind it is the 
willingness to create a more competitive and cost efficient entity that is able to gain a higher 
market share. However, special attention should be devoted to the synergy’s creation which 
can take either the form of revenue enhancement or cost saving. Companies usually aim at 
reaching new market opportunities and industry visibility while achieving economies of scale 
and acquiring new technology. Looking in deeper detail, the examined sector shows a great 
number of completed takeovers over the considered period of time. It can be explained by the 
difficulty to commercialize new drugs in the market: it takes several years and has a high risk. 
As a matter of fact, there are low probabilities of finding new compounds and regulators 
requires always greater standard.  
Strategic and research questions have been developed in order to build up a well-organized 
empirical project.  
Strategic question Research Question 
Did Pfizer-Wyeth merger create value for 
shareholders when compared to the 
pharmaceutical sector? 
To what extent do financing structure, EPS 
and transaction size impact M&A success 
and thus company performance? 
 
The paper is structured in the following way: the second section investigates the existing 
literature related to M&A issues. The third section discloses what type of data have been used 
and where they come from. The fourth section examines the methods used to carry out useful 






2. Literature Review 
2.1. Mergers and Acquisitions: definitions and types 
Merger and acquisition (hereafter M&A) is a widespread expression which refers to a 
company’s consolidation and involves numerous agreements such as mergers, acquisitions, 
purchase of assets and tender offers. As reported by Faulkner, Teerikangas and Joseph (2012) 
merger can be defined as the combination of two companies to create a new enterprise 
whereas an acquisitions refers to the buying of one firm by another and it does not consider 
the foundation of any new business. Ross, Westerfield and Jaffe (2003) introduced a legal 
framework according to which M&A can be classified as mergers or consolidations, 
acquisitions of stocks and acquisition of assets. In the former case, merger is the combination 
of two companies in which only one survives while the other goes out of existence (A+B=A) 
while consolidation is described as a transaction in which both the pre-existing entities are 
legally dissolved and they are going to join creating a new firm (A+B=C). In an acquisition of 
stocks, the acquiring enterprise’s management makes an offer to the target’s board of 
directors for the target’s shares. It can either be friendly or hostile. In the latter case, the 
acquiring firm purchases all the target’s company assets.  
However, M&A can also be sorted out in line with the financial analyst classification which 
considers horizontal, vertical and conglomerate mergers (Tremblay and Tremblay 2012). 
While horizontal and vertical mergers consider businesses that are related to each other, 
conglomerate combination occurs when two entities do not have any point of contact (Higgins 
and Schall 1975). Moreover, vertical merger takes place whether both acquiring and target 
enterprises compete in the same sector while vertical merger happens when two firms are at 






2.2. M&A Activity  
Companies regularly engage in M&A in the expectation of improving their performance and 
their competitive position. Over time, the number of M&A activities has increased a lot 
reaching a new high in 2015 (Rhem and West 2015). Looking in deeper details, more than 
7500 transactions had been announced, exceeding 2014 business combination volume by 8%. 
The deals majority occurred in US even though the Asian market had huge impact on the 
overall capacity. However, it is crucial to highlight the reasons that are prompting enterprises 
promoting M&A and how they gradually changed. While in the past deals were considered as 
tactics to boost industry consolidation and cost reduction, nowadays, managers are talking 
about diversification, cross selling and creation of new customer opportunities. It means that 
transactions are actually considered as strategic tool to raise revenues, promote growth and 
enable enterprises to expand themselves into more lucrative businesses. Nevertheless, it is 
important to keep in mind that the main objective of any deals is to create value for all firm’s 
stakeholders and principally for shareholders of the acquiring company. Truthfully, there is a 
debate among scholars related to the extent to which M&A transactions create value. As a 
matter of fact, there is not a unique frame of reference since there is a long history of failed 
deals. However, this great degree of collapse does not turn out in all sectors. This research 
paper is aimed at assessing whether the pharmaceutical industry is in line with this high M&A 
failure rate. Since 1980s, many pharmaceutical companies were involved into M&A 
takeovers leading to the foundation of the so called Big-Pharma. Having this background, 
there are some factors that have an impact on the enterprise’s decision to initiate a business 
combination process such as growing claim for generic products, loss of earnings from patent 






2.3. Valuation: stand-alone entity and synergies 
Companies implement several strategies in order to speed up their growth, become more 
profitable and support value creation. Among these tactics, M&A has always been an 
essential factor and firms continue to be engaged in such transactions because of the upside 
they could show such as synergistic gains, diversification and raised growth (Vulpiani 2014). 
However, several takeovers are actually destroying value but is seems that managers forget 
about possible downsides. Since this paper mainly focus on value creation, it is crucial to 
understand what this term actually means.  
The company’s ultimate objective is to maximize value (Damodaran 2011) because it is a 
valuable benchmark of the firm accomplishments (Koeller, Goedhart and Wessel 2010). 
Substantially, it considers long term interest of all firm’s stakeholders and it enables to 
achieve greater degree of customer satisfaction. According to the literature, M&A transaction 
creates value and maximizes returns whether expected synergies plus stand-alone value of the 
target are higher than the price paid for the target.  
                      Value creation = (Synergies + Stand-alone value of the target) >          (2.1)            
 (Acquisition Premium + Market Value of the target) 
There are quite a few analysis that can be carried out in favor of a clear comprehension on 
whether M&A produces value, such as the semi-strong investigations. These event studies are 
going to assess abnormal returns in the period before and after any business combination 
announcement. There are two key results from these examinations: 
- Acquiring firm stockholders gain zero or negative abnormal return yields from M&A. 
The main reason behind this statement is that market skeptical reaction is typically 
related to synergistic gains; 
- Target stockholders gain positive abnormal return yields from friendly M&A. The 




premiums earned by target shareholders; 
The above mentioned propositions primarily lead to the finding that M&A usually do not 
create value for acquiring shareholders. Anyhow, further features should be taken into 
account such as financing structure, EPS impact and transaction size. In order to have a fair 
understanding, it is essential to test the existing relationship between M&A success and 
business performance using the following hypothesis: 
Financing structure: form of payment can affect transaction success and thus returns for 
shareholders. In particular, deal value can either be paid in cash or in stock. According to 
Hazelkorn, Zenner and Shivdasani’s paper (2004), equity market’s reaction varies a lot 
depending on the method with which a takeover is funded: cash-financed acquisitions lead to 
positive returns for shareholders of the acquiring company compared to stock-financed 
agreements. There are several motives that justify this trend, such as the fact that cash-paid 
business combinations give positive signals to investors about the ability to restore the cash 
balance (Amihud, Lev and Travlos 1990) and the fact that stocks are usually used when 
shares are overvalued (Zhang 2001). However, Sehgal et al. (2012), proposed an opposite 
idea, according to which stock financed mergers are value creating while, on the other hand, 
cash financed deals seem to be value destroying in the BRICKS market. Nevertheless, this 
paper follows the suggestion of cash financed oriented takeovers. 
Hypothesis 1: Ceteris paribus, cash financed transactions will improve company 
performance. 
EPS impact: EPS is an essential element. Usually, firms are looking for non-dilutive to 
earnings business combinations because they are considered negatively by investors (Andrade 
1999). However, there are some studies which do not consider it as a key factor. As a matter 
of fact, although accretive deals perform better than dilutive ones in both short and long run, 




2004). According to this theory, much importance should not be assigned to EPS accretion in 
evaluating deal success because EPS will not impact acquirer returns in the way predicted by 
conventional wisdom and thus is not going to predict value creation. 
Hypothesis 2: Ceteris paribus, EPS negatively impacts company performance. 
Transaction size: there are some studies which suggest a kind of relationship between 
transaction size and short term success, finding a statistically significant connection among 
them. This phenomenon appears particularly important in cross-listed firms which use equity 
(Tolmunen and Torstila 2008). However, looking at long term success this correlation does 
not appear anymore (Hazelkorn, Zenner and Shivdasani 2004). 
Hypothesis 3: Ceteris paribus, transaction size negatively impacts company performance. 
 
3. Data and sample selection  
This paper is based on data related to publicly listed companies operating worldwide even 
though their headquarters are mostly established in Europe or in the United States. 
A sample of twenty completed transactions was determined by using Zephyr, one of the most 
extensive database of deal information. The representative includes organizations running 
their business in the pharmaceutical sector and it does not consider corporations operating in 
the financial industry. The reason behind this choice is motivated by both the regulatory 
nature of the financial service sector and the decision to assess how firms behave in the 
analyzed industry. The chosen sample includes mergers and acquisitions but does not 
consider neither IPO, institutional buy-out, capital increase nor management buy-in/buy out. 
All the takeovers were announced between January 1, 2000 and January 1, 2016 and were of 
relevant size, meaning that their deal values were at least US$ 150 million. Furthermore, it 
considers either acquirer, target or vendor from all over the world and acquirers are listed in 




After having completed this first step, data related to the examined firms was downloaded 
from Bloomberg and it is now available for the empirical study. In order to perform the 
second step analysis, data related to enterprise’s performance measures were collected for 
each company from the DataStream for the 2015 financial year. In particular, information 
associated to financing structure, EPS impact and transaction size were taken. The impact of 
such characteristics was then evaluated through the use of data regression for each 
enterprise’s stock market performance (proxied by Tobin’s q ratio). However, prior to 
conduct the second step analysis it is essential to determine whether the chosen sample is 
suitable for applying a multiple regression. Firstly, data are examined in order to check for the 
existence of several essential hypotheses that could grant trustworthy findings using SPSS 
Statistics. The Central Limit Theorem is valid which means that it can be possible to assume 
that the distribution of the estimates is close to a normal distribution. As a matter of fact, the 
linear regression assumption has been verified through the use of a scatterplot (the residuals 
fits the normal distribution line) which guarantees a linear relationship among dependent and 
independent variables. According to Phillips (1986), it is helpful to use Durbin Watson 
Statistic in order to guarantee variables’ independence. In particular, it assures that there is no 
correlation in the selected representative since its value is equal to 1.957. Furthermore, 
following what is suggested by Jarque and Bera (1980) all records have been subjected to 
homoscedasticity. Then, it has been checked that independent variables are not extremely 
correlated with each other through the use of the Variance Inflation Factor (VIF). Truthfully, 
in the examined case there is no multicollinearity because independent variables’ VIF value is 
between 1.057 and 1.227 which is not close to 10. According to the last assumption, it is 
necessary to take out meaningful outliers in order to increase model’s predictive precision. 
This hypothesis is checked through Mahalanobis Distance which should be lower that 16.27. 




above-mentioned critical value. 
The dataset is composed by 20 observations taken from the sample over the examined period 
of time. Looking in deeper details, the following values were taken for each enterprise: 
• Tobin’s q ratio: it is a measure of firm performance at the financial market level which 
takes the stock market into consideration. It is taken by Bloomberg even if it can be 
computed using the following formula: !"#$%&	()*+,%	-).#,!"#$%&	/00+	-).#, 		; 
• Financing structure: it refers to the transaction’s form of payment which can either be 
in cash or in stock. In the former case it takes a value 1, and 0 otherwise; 
• EPS impact: it is the share of a firm’s earnings that is distributed to each share of 
common stock. It is an important factor in determining share’s price; 
• Transaction size: it refers to M&A transaction value taken from Zephyr database 
(figures are in million of euro); 
The following table (Table 1) is going to represent the summary statistics for the principal 
variables used in the regression analysis. 
Table 1: Summary statistics 
 
Source: SPSS Statistic 
This research is performed by using computational and mathematical processes and therefore 
the candidate is hoping to obtain unbiased outcomes that can be generalized to a most 





4. Empirical model 
In order to test if the specific event study created value for shareholders of the acquiring firm, 
stock excess returns are measured considering distinct time horizons. Theoretically speaking, 
excess stock returns can be defined as the total stock’s actual return adjusted for general 
market wide movements, evaluating if the share reacted positively at the announcement date 
of acquisition and principally, if acquirer’s share exceeds its peers in the long period. In favor 
of a clear understanding, it is crucial to measure abnormal returns for the target acquisition 
and for each stock in the sample considering both short term and long term timelines 
surrounding the announcement (Huang. Y.S. and Walking 1987). Starting from a short term 
investigation, two distinct timeframes are considered which are five-day window (it begins 
two-days prior the announcement and it finishes two-days after it) and 21-day window (it 
starts ten-days before the announcement and it finishes ten-days after it). The rationale behind 
the computation of 21-day window is that significant features are only openly revealed after a 
period of time. 
However, this research paper is also going to analyze the stock market’s response to business 
combination over a longer period of time. As a matter of fact, an extended frame of reference 
enables to capture post-merger integration and execution aspects that otherwise are not 
considered. In particular, these features complement the work supporting the success of a 
transaction. Following the paper’s direction, excess returns are computed over one-year 
window (it begins right after the announcement date and it finishes one year later) and two-
year window (it starts right after the announcement date up to two years after). Following 
there is an explanation of the method used to calculate them. 
Bloomberg is the financial software used to download data related to target company and each 
enterprise included in the sample. At the beginning, both daily and weekly stock prices in 




refer to the short term investigation (five-day window and 21-day window) whereas weekly 
stock prices consider longer time frame (one-year window and two-year window). Then, 
MSCI World Index was chosen as a proxy for the market return needed to adjust abnormal 
returns for market movements, and US Government Bonds 10-years yield’s Index was 
picked out as the risk free asset used to measure excess returns (Bloomberg tickers are 
respectively: MXWO World Index and USGG10YR). There are two reasons that justify MSCI 
World Index’s selection: it is a measure of equity market performance of developed markets 
and all pharmaceutical companies selected in the sample have operations all over the world.  
The next step is to evaluate stock returns for each company, for risk free asset (USGG10YR) 
and for market proxy (MXWO World Index) starting from their prices. As a matter of fact, 
the return analysis enables a comparison among all variables. It is more convenient to 
compute log returns instead of raw returns because they have several benefits such as log-
normality, approximate raw-log equality, time-additivity and numerical stability (Berk and De 
Marzo 2014). Moving forward, excess returns are measured for each enterprise as the 
difference between stock’s returns and return on the risk free asset in order to estimate if the 
specific yield exceeds the benchmark (USGG10YR). Afterward, market excess returns are 
evaluated as the variation of USGG10YR yields from the MSCI World Index returns. 
Once all these calculations have been performed, Pfizer’s beta is computed according to the 
Capital Asset Pricing Model. It means that Pfizer’s returns are regressed against returns on the 
market index (MSCI World Index) over a reasonable time period preceding deal’s 
announcement date. Actually, there is not a unique time period used to estimate betas: 
depending on the industry it can be set between three and ten years. Surely, higher is the 
number of observations in the regression, greater is the relevance level when beta is 
calculated. Specifically, 5-years time frame is usually chosen for firms that have been 




assessed (Fama and French 2004), leading to the evaluation of Pfizer’s expected returns 
(Damodaran 1999). In particular, one-day expected return is equal to: 
Expected Returns= α + β * (Market excess returns)                                                            (4.1) 
Then, one-day abnormal returns are computed as shown in the equation below: 
Abnormal Returns= Actual Returns – Expected Returns                                                      (4.2) 
Once one-day abnormal returns are measured for the specified period of time, it is reasonable 
to consider total abnormal returns. It is computed for each enterprise included in the sample 
as the sum of all abnormal returns over the examined horizon. 
As soon as short term analysis is concluded, it is rational to pass through long term horizon 
appraisal. The extended length of time leads to discuss further beneficial consideration such 
as post-acquisition synergies, integration practices and execution policies. All of them are 
crucial for the success of any specific transaction as well as for value creation related to 
business combination. The majority of scholars who have researched M&A success rate 
believe that most of them did not produce any gain for shareholders and that they are actually 
destroying value. Looking at firms reports, more than half failures may be ascribed to 
organization concerns including leadership clash, loss of key talent, lack of management 
commitment, poor communication, misaligned structured and lack of shared vision. In order 
to avoid any kind of problems during post-merger phase and ensure the greatest possible 
coordination among companies involved in the takeovers, the M&A team should carefully 
schedule all activities subsequent to the alliance. 
According to the chosen methodology, there are other two time intervals that should be 
investigated: one-year horizon and two-year horizon. While the first one begins 
immediately after the announcement date and finishes one year later, the second one starts in 
the same moment as the former and spreads out up to two years after the pronouncement. The 




except for one aspect: abnormal returns are measured using both market indices, MSCI Health 
Index (Bloomberg ticker: MXWOOHC Index) and MSCI World Index. In particular, the first 
one is used to relate Pfizer’s stock return to its peers within the pharmaceutical sector, while 
the second one is orientated to evaluate stock market response to Pfizer announcement in the 
long run. 
Looking at the regression analysis, its main objective is to assess whether three factors 
(financing structure, EPS impact and transaction size) have an impact on company stock 
market performance (Tobin’s q ratio) in periods surrounding the announcement of the deal so 
that they can affect M&A success. Tobin’s q ratio was taken to evaluate firm performance in 
the chosen sample. At the beginning, some tests were implemented through a correlation 
analysis in order to estimate the existing link among variables. Then, a multiple regression 
model was performed to evaluate the extent to which the examined independent variables 
affect the dependent one. It is explained by the following equation:  
Yit = β0 + β1 FINSTRUC - β2 EPS - β3 TRANSIZE + εit                                                                          (4.3) 
(i=1,…,n; t=1,…m) 
According to what already has been argued in the literature review section, below there are 
the hypothesized findings that have been checked through the regression analysis.  
Hypothesis 1: financing structure has a positive impact on company stock market 
performance and thus on M&A success; 
Hypothesis 2: EPS has a negative impact on company stock market performance and thus on 
M&A success; 
Hypothesis 3: transaction size has a negative impact on company stock market performance 






The regression model results are shown in Table 2. 
Table 2: Regression variable estimates 
   
Source: SPSS Statistic 
 
5. Results and Interpretation 
5.1. First step analysis: does M&A create value? 
After having performed all the above calculations, it is rational to briefly discuss the main 
results related to both the Pfizer case study and the pharmaceutical industry. Starting from the 
Pfizer’s analysis, it created value for the company’s shareholders. Looking at the Table 3, 
even though abnormal returns related to the 5-day window were negative they changed into 
positive during the next ten days.  
Table 3: Pfizer’s Abnormal Returns for Short-term and Long-term Horizons 
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-13,20% 9,61% 33,08% 22,65% 47,00% 51,59% 
Source: Calculated using data taken from Bloomberg database 
Usually, M&A announcements have negative impacts on stock price considering short period 
of time surrounding the announcement. To reinforce this theory, Figure 1 shows Pfizer’s 
cumulative excess returns in the short horizon. As a matter of fact, the graph has a negative 




Figure 1: Average Cumulative Excess Acquiror Stock Returns Relative to Announcement 
Date of M&A Transactions 
 
Source: Calculated using data taken from Bloomberg database 
 
There are several reasons that justify the negative short-term excess returns in the 5-day 
window after the announcement of the deal (Bradley, Desai and Han 1983): some of them 
depend on sceptical market reactions, while others are based on cultural, operational and 
financial explanations (De Noble, Gustafson and Hergert 1988). Firstly, some factors lead to 
lower abnormal returns such as the fear of a possible cultural conflict that could arise because 
of different company structures, the Wyeth CEO’s lay-off and the plan to integrate the 
Wyeth’s expertise into the new Pfizer organization, the fact that both enterprises mainly 
operated in US and the reduced reliance on Pfizer’s primary care medicines. Further key 
issues are based on the contraction of diluted EPS (because of litigation-related matters), the 
decreased proportion of Pfizer’s revenues that comes from primary care product and the 
foreign exchange which shrinkage firms’ revenue. As soon as Pfizer was able to manage these 
difficulties, returns became positive increasing in the long run. As a matter of fact, the deal 
meaningfully advanced business’s strategic priorities which include the enhancement of 




industry (Kronimus, Nowotnik, Roos and Stange 2001). Furthermore, it accelerated the 
enterprise’s growth in emerging markets, leading to the creation of new opportunities in these 
businesses and enabling the investment in complementary sectors with lower cost base 
(Bruner 2004). Geographically speaking, the enterprise’s combined footprint is unequalled, 
being present in the US, Europe, Asia, Brazil and Russia. In addition, the takeover extended 
the firm’s global healthcare leadership. In fact, Pfizer established itself as a leader in animal, 
human and consumer health, promoting bio-therapeutics and vaccines innovation and being 
the top player in primary care and the number two enterprise in specialty care worldwide. 
This success was achieved thanks to the combination of a well diversified giant like Pfizer 
with the speedy and agility of the smaller Wyeth: they were able to connect discipline, 
accountability and strong commitment. It was done through the establishment of business 
units, each one having a clearly defined leader and focused on one customer segment. It 
benefits from fixed costs of research, manufacturing and commercialization that promote 
investment and maintain financial flexibility at the same time. The result is a company with 
relevant resources and scale and a great competitive advantage over its rivals. It has a broader 
portfolio composed by innovative products and occasion for growth. 
Summing up, Pfizer-Wyeth takeover seems to be the right transaction, at the right time, with 
the right firms and for the right reasons. Even though total abnormal returns were negative 5-
days after the announcement date, they turned into positive ones because of synergies related 
to the transaction: these come from R&D and manufacturing, which include the 
implementation of a global procurement structure, support functions, economies in back-
office operations, sales and manufacturing and the establishment of a global network of 
plants. It means that the business combination created value not only for the shareholders of 
the acquiring company, but also for customers and patients today, patients tomorrow and 




By joining together, “we created the world’s premier biopharmaceutical company whose 
distinct blend of diversification, flexibility and scale proportion” (Pfizer 2009). 
 
5.2. Conclusion on Pfizer-Wyeth deal and M&A in the Pharmaceutical sector 
Looking again at Table 1, it is possible to highlight that MSCI Health Index achieved greater 
results in both 1-year window and 2-year window compared to MSCI World Index. It means 
that Pfizer accomplished better outcomes than the thorough pattern of its peers within the 
pharmaceutical industry. In order to evaluate whether pharmaceutical sector produces value, 
two frequency distribution charts are drawn representing abnormal returns’ allocation for 
shareholders of the acquiring firms. Figure 2 exhibits frequency distribution of short-term 
abnormal returns, while Figure 3 shows long term frequency distribution. 
 
Figure 2: Frequency distribution of Short-term Abnormal Returns 
 
Source: Calculated using data taken from Bloomberg database 
Let us go through the graph explanation. The vertical axis represents frequency for specific 
range of values, while horizontal axis stands for short-term abnormal returns. In the graph, 
both 5-day window and 21-day window are displayed using different colours (blue bar for 5-




usually 5-day excess returns are close to zero or negative: only few transactions show positive 
returns, whereof the greatest value is 10%. As above described it can be justified by several 
reasons such as cultural, operational and financial fears. The crucial aspect is that total 
abnormal returns turn into positive after a period of time. As the chart exhibits, already 10 
days after the announcement returns increased: in the chosen sample there is only one out of 
twenty negative excess return related to the 21-day window. 
However, there are some factors that positively impact a takeover’s success such as the form 
of payment and earning growth determinants, as well as if the target company is domestic or 
foreign and whether the business combination is focused or diversified. Following, further 
details are provided. The transaction was mainly financed by cash and the target company 
was a mature enterprise. As a matter of fact, buyers achieve higher industry-adjusted returns 
when the objective company’s projected earning-growth rate is low because they are able to 
increase shareholders value through operational synergies. In addition, also the target firm 
status matter. There are some rationales behind it: private company and acquisition of asset or 
business units are narrower in scope compared to public and whole enterprise acquisitions and 
thus less predisposed to integration difficulties. Furthermore, they are usually paid in cash 
rather than through stock (as above described, cash financed transactions are more prone to 
add value than stock financed business combination). Moreover, other two aspects should be 
considered: foreign target firms versus domestic ones and focused versus diversified business 
combinations. Regarding the former, foreign firms earn greater returns because they are able 
to reach broader geographic scope for their enterprise’s products while, in the latter, focused 
business achieves better results because of synergies in costs and revenues and because of 
cultural and social similarities. 
Turning the attention to the long run horizon, it is crucial to highlight that MSCI Health Index 




combination involving pharmaceutical companies do not only create value for shareholders of 
the acquiring firms but also for the entire market. 
Looking at Figure 3, it is possible to assess frequency distribution related to long-term excess 
returns. It refers to MSCI Health Index, meaning that it evaluates abnormal returns for the 
specific industry (Loughran and Vijh 1997). 
 
Figure 3: Frequency distribution of Long-term Abnormal Returns using MSCI Health Index 
 
Source: Calculated using data taken from Bloomberg database 
 
Analysing the histogram, we can infer that almost all deals tend to have positive long term 
abnormal returns. It means that almost all business combinations performed within the 










5.3. Second step analysis: regression model results 
In this analysis a hierarchical ordinary least square regression is performed in order to assess 
the impact of three independent variables on company performance. As already discussed, 
firm performance is proxied by Tobin’s q ratio which is considered as the dependent variable 
for the model. This study considers twenty pharmaceutical deals which are evaluated over 
2015 financial year. 
Looking at the regression analysis, it is important to conclude that stock market performance 
improves if the transaction is financed by cash rather than stock. This finding reinforces the 
above postulated hypothesis 1. Furthermore, greater are EPS and transaction size greater is 
the negative impact company performance. Therefore, regression results support both 
hypothesis 2 and hypothesis 3. 
Table 4 shows the results of the regression study whose aimed at predicting company 
performance. Surely, observations are well described by the model because the Adjusted R-
Square is equal to 0.851 which is close to 1.  
 
Table 4: Model summary 
 










The main conclusions of this empirical research are based on quantitative analysis and are the 
following: 
- 5-days abnormal returns related to the Pfizer-Wyeth case study are negative;  
- 21-days abnormal returns related to the Pfizer Wyeth case study are positive; 
- 5-days abnormal returns related to the pharmaceutical sector are usually close to zero 
or negative, displaying few positive values whereof the greatest is 10%; 
- 21-days abnormal returns related to the pharmaceutical sector are positive, showing 
only one exception; 
- MSCI Health Index reaches higher values in both 1-year and 2-year windows 
compared to MSCI World Index; 
- 1-year and 2-year abnormal returns related to the MSCI Health Index are positive; 
- Financing structure positively impacts company performance and thus M&A success; 
- EPS negatively impacts company performance and thus M&A success; 
- Transaction size negatively impacts company performance and thus M&A success; 
 
As overall conclusion, it seems that the Pfizer-Wyeth deal created value for shareholders of 
the acquiring company, being aligned to the pharmaceutical industry trend. In fact, the 
rationale behind M&A operations comes from both acquirer and target companies: Big-
Pharma are usually able to obtain better funding than small or biotech firms. On the other 
hand, the latter enterprises are distinguished by an entrepreneurial spirit which encourages 
R&D investment leading to new drug mass production. 
Finally, it should be underlined that the results are representative of the pharmaceutical sector, 
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